ArticleColloids and surfaces. B, Biointerfaces2021
Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2.
Article in Colloids and surfaces. B, Biointerfaces, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Potential ofBioMed research international · 2022Pooled it
- Assessment of Bovine Herpesvirus Type 1 (BoHV-1) Stability and Infectivity on Copper, Zinc, and Stainless Steel Surfaces.Veterinary sciences · 2026Article
- Nanotechnology-Enhanced Delivery and Bioactivity of Dietary Flavonoids: Overcoming Bioavailability Barriers for Targeted Antimicrobial and Antiviral Therapies-A Comprehensive Review.International journal of nanomedicine · 2026Review
- Comparison of Peganum harmala L. leaves extract nanoformulations against herpes simplex virus type 1 guided by network pharmacology analysis.Scientific reports · 2025Article
- Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure.Pathogens (Basel, Switzerland) · 2025Article
- Eco-friendly fabrication of ZnO quantum dots using Brassica rapa (L.): metabolomic profiling and antimicrobial efficacy against foodborne pathogens supported by in-silico insights.Scientific reports · 2025Article
- Nasal Spray Disinfectant for Respiratory Infections Based on Functionalized Silver Nanoparticles: A Physicochemical and Docking Approach.Nanomaterials (Basel, Switzerland) · 2025Article
- Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.Nanomedicine (London, England) · 2025Review
- Antioxidant Nutraceuticals: Their Adjunct Role in the Management of COVID-19 Infections and Post-COVID Syndrome.Infectious disorders drug targets · 2025Review
- InBiochemistry and biophysics reports · 2024Article
- Comparative metabolomics analysis ofHeliyon · 2024Article
- Hesperidin, a Potential Antiviral Agent against SARS-CoV-2: The Influence of Citrus Consumption on COVID-19 Incidence and Severity in China.Medicina (Kaunas, Lithuania) · 2024Review
- Nanoparticle‑based antiviral strategies to combat the influenza virus (Review).Biomedical reports · 2024Review
- Article
- Bio-fabricated zinc oxide nanoparticles mediated by endophytic fungusFrontiers in microbiology · 2024Article
- Evaluation of the antiviral activity of ultraviolet light and zinc oxide nanoparticles on textile products exposed to Avian coronavirus.Scientific reports · 2023Article
- Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.Heliyon · 2023Review
- Advancements of Nanotechnology and Nanomaterials in Environmental and Human Protection for Combatting the COVID-19 During and Post-pandemic Era: A Comprehensive Scientific Review.Biomedical materials & devices (New York, N.Y.) · 2023Review
- Implication of nanotechnology to reduce the environmental risks of waste associated with the COVID-19 pandemic.RSC advances · 2023Review
- Current Update on Role of Hesperidin in Inflammatory Lung Diseases: Chemistry, Pharmacology, and Drug Delivery Approaches.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the coronavirus (COVID-19), is the virus responsible for over 69,613,607 million infections and over 1,582,966 deaths worldwide. All treatment measures and protocols were considered to be supportive only and not curative. During this current coronavirus pandemic, searching for pharmaceutical or traditional complementary and integrative medicine to assist with prevention, treatment, and recovery has been advantageous. These phytopharmaceuticals and nutraceuticals can be more economic, available, safe and lower side effects. This is in silico comparison study of ten phenolic antiviral agents against SARS-CoV-2, as well as isolation of the most active metabolite from natural sources. Zinc oxide nanoparticles (ZnO NPs) were also then prepared using these metabolite as a reducing agent. All tested compounds showed predicted anti-SARS-CoV-2 activity. Hesperidin showed the highest docking score, this leads us to isolate it from the orange peels and we confirmed its structure by conventenional spectroscopic analysis. In addition, synthesis of hesperidin zinc oxide nanoparticles was characterized by UV, IR, XRD and TEM. In vitro antiviral activity of hesperidin and ZnO NPs was evaluated against hepatitis A virus as an example of RNA viruses. However, ZnO NPs and hesperidin showed antiviral activity against HAV but ZnO NPs showed higher activity than hesperidin. Thus, hesperidin and its mediated ZnO nanoparticles are willing antiviral agents and further studies against SARS-CoV-2 are required to be used as a potential treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.